VB-111 Non-replicating Adeno 5 vectors / Indication : Cancer


2017.11.3 NanoCarrier and VBL Therapeutics Conclude License Agreement for Gene-Therapy Agent in Japan

  • Non-replicating Adeno 5 vectors
  • Systemically administered via intravenous injection
  • Selectively induce cell death in angiogenic endothelial cells
  • Triggers a local anti-tumor immune response
  • POC verified for other solid cancers

VB-111 Trailer

(Please note that sound will flow)

Development by VBL is progressing mainly in the United States.

Vascular Biogenics Ltd. (VBL) operationg as VBL therapeutics

VB-111 Platform